These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 216479)

  • 1. Multiple pulmonary lesions in a patient treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) for glioblastoma multiforme.
    Bellot PA; Valdiserri RO
    Cancer; 1979 Jan; 43(1):46-50. PubMed ID: 216479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
    Mitsudo SM; Greenwald ES; Banerji B; Koss LG
    Cancer; 1984 Aug; 54(4):751-5. PubMed ID: 6744207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary fibrosis: a complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.
    Ryan BR; Walters TR
    Cancer; 1981 Aug; 48(4):909-11. PubMed ID: 7272934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
    Selker RG; Jacobs SA; Moore PB; Wald M; Fisher ER; Cohen M; Bellot P
    Neurosurgery; 1980 Dec; 7(6):560-5. PubMed ID: 7207751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme.
    Bashir R; Hochberg FH; Linggood RM; Hottleman K
    J Neurosurg; 1988 Jun; 68(6):917-9. PubMed ID: 2836567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane and cytoplasmic changes in 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)-sensitive and resistant human malignant glioma-derived cell lines.
    Smith BH; Vaughan M; Greenwood MA; Kornblith PL; Robinson A; Shitara N; McKeever PE
    J Neurooncol; 1983; 1(3):237-48. PubMed ID: 6088716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor bed cyst formation after BCNU wafer implantation: report of two cases.
    Engelhard HH
    Surg Neurol; 2000 Mar; 53(3):220-4. PubMed ID: 10773252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain.
    Kessinger A; Lemon HM; Foley JF
    J Surg Oncol; 1978; 10(6):543-7. PubMed ID: 215846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
    Brandes AA; Tosoni A; Amistà P; Nicolardi L; Grosso D; Berti F; Ermani M
    Neurology; 2004 Oct; 63(7):1281-4. PubMed ID: 15477552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.
    Hochberg FH; Parker LM; Takvorian T; Canellos GP; Zervas NT
    J Neurosurg; 1981 Apr; 54(4):455-60. PubMed ID: 6259300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology of high-dose intraarterial BCNU.
    Kleinschmidt-DeMasters BK; Geier JM
    Surg Neurol; 1989 Jun; 31(6):435-43. PubMed ID: 2541513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
    Subach BR; Witham TF; Kondziolka D; Lunsford LD; Bozik M; Schiff D
    Neurosurgery; 1999 Jul; 45(1):17-22; discussion 22-3. PubMed ID: 10414561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
    Levin VA; Wara WM; Davis RL; Vestnys P; Resser KJ; Yatsko K; Nutik S; Gutin PH; Wilson CB
    J Neurosurg; 1985 Aug; 63(2):218-23. PubMed ID: 2991486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
    Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
    Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling.
    Rhee CH; Ruan S; Chen S; Chenchik A; Levin VA; Yung AW; Fuller GN; Zhang W
    Oncol Rep; 1999; 6(2):393-401. PubMed ID: 10023010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nitrosourea-induced lung diseases].
    Massin F; Coudert B; Foucher P; Lombard JN; Reybet-Degat O; Jeannin L; Camus P
    Rev Mal Respir; 1992; 9(6):575-82. PubMed ID: 1470749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of clonogenic human brain tumour cells: preliminary results of tumour sensitivity testing with BCNU.
    Rosenblum ML; Dougherty DA; Deen DF; Hoshino T; Wilson CB
    Br J Cancer Suppl; 1980 Apr; 4():181-5. PubMed ID: 6252931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.